Enable JavaScript to visit this website.

There is no more effective treatment to help your patients quit smoking.1-4

CHAMPIX offers significantly improved abstinence rates vs. single and combination NRT1*

This meta-analysis looked at 146 RCTs with at least 3 months follow-up post-quit date:

• 65 of standard-dose nicotine patch (≤22mg)

• 6 of high-dose NRT patch (>22mg)

• 5 of high-vs. standard-dose NRT patch

• 5 of NRT patch plus another formulation vs. inert controls

• 6 of NRT patch plus another formulation vs. single NRT patch

• 48 of bupropion

• 11 of CHAMPIX1

 

The only RCT (open-label) with head-to-head comparison of 12 weeks of CHAMPIX vs. 10 weeks of nicotine replacement therapy (NRT) patch (NiQuitin CQ® Clear) with follow up at 1 year demonstrated a statistically significant difference in favour of CHAMPIX at 3 months, but significance was not achieved at 6 or 12 months.3

* At ~4 weeks, 3 months and 12 months (and vs. standard-dose (≤22mg) NRT patch at 6 months).1 
This Baysian multiple treatment comparison encompasses both indirect and direct treatment comparisons and requires the following assumptions: homogeneity (populations and diseases were appropriate to combine), similarity (trials measured similar outcomes), and consistency (findings of direct and indirect evidence were not importantly different). 
Data presented as Odds Ratio only as pairwise results for all comparisons not available.


 

Who can benefit from Champix?

Smokers with and without psychiatric history 

 

Smokers with Chronic obstructive pulmonary disorder (COPD) or Cardiovascular disease (CVD) 

1. Mills, EJ et al. Comparisons of high dose and combination nicotine replacement therapy, varenicline and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann Med 2012; 44: 588-597.
2. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews 2013; Issue 5. Art. No.: CD009329. DOI:10.1002/14651858.CD009329. pub2.
3. Aubin, HJ et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. 2008; Thorax 63: 717–724.
4. Anthenelli, RM et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. 2016; Lancet 387: 2507-2520.

PP-CHM-GBR-1788. April 2018.

CHAMPIX efficacy vs NRT